Shares of Tharimmune Inc (NASDAQ:THAR) are surging in Monday afternoon trading, continuing a rally that began last week. The stock’s rise comes in the absence of any company-specific news for the session, but follows last week’s announcement of promising simulation results for its lead clinical asset, TH104.
What To Know: TH104, a novel buccal film formulation of nalmefene, is being developed as a prophylactic countermeasure for military personnel and first responders who may be exposed to high-potency opioids like fentanyl.
